Impact factor jama oncol
WitrynaLancet Oncology Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1470-2045. ... Journal Impact. Enter journal title, issn or abbr in this box to search. Lancet Oncology. Journal Abbreviation: LANCET ONCOL Journal ISSN: 1470-2045. Year: Impact Factor (IF) Total Articles: Total Cites: ... Jama-Journal of The ... Witryna23 mar 2024 · JAMA Oncology—The Year in Review, 2024 Oncology JAMA Oncology JAMA Network This past year has been an exciting one for JAMA Oncology and its …
Impact factor jama oncol
Did you know?
WitrynaThis cohort study analyzes data from the National Cancer Database to evaluate the factors associated with higher mortality rates among men with breast cancer co ... JAMA Oncol. 2024;5(11):1589–1596. doi:10.1001 ... 1.72; 95% CI, 1.67-1.77; P for time-varying effect = .86). Age-adjusted HR for total mortality among male compared with … WitrynaThe impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of …
Witryna24 mar 2024 · Impact factor 3.467 (2024) Five year impact factor 23 days Submission to first decision (Median) 335,089 (2024) Downloads. Latest issue. Volume 28. Issue 4, April 2024 View all volumes and issues. Latest articles. The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of … WitrynaThe journal’s impact factor of 31.8 placed us as one of the highest-ranking oncology journals. Choosing the best articles for the journal was rewarding but challenging. We …
Witryna9 lis 2024 · Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. ... or orchiectomy. 2 While, consideration of the adverse effects associated with each of these therapies is a recommended consideration, ... JAMA … Witryna1 lis 2024 · Importance: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, setting, and participants: This single-center, randomized …
Witryna1 gru 2024 · Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial ... JAMA Oncol. 2024 Dec 1;4(12):1729-1735 ... Treatment was outpatient with reversible neuropathic pain and without unexpected toxic effects. No …
WitrynaThe Lancet Oncology is an internationally trusted source of clinical, public health, and global health knowledge. With an Impact Factor of 54·433, we are the world-leading clinical oncology research journal globally (2024 Journal Citation Reports ®, Clarivate 2024). We recognise that the Journal Impact Factor is just one measure of a journal ... troubleshoot kitchenaid mixerWitrynaMain Outcomes and Measures Overall survival time and all-cause mortality. Results Median (range) age of 3241 women included in this study was 54 (18-80) years, and … troubleshoot kitchenaid ice makerWitryna11 lis 2024 · This cohort study compares the toxic effects and oncologic outcomes associated with intensity-modulated radiation therapy (IMRT) vs intensity-modulated proton t ... JAMA Oncol. 2024;8(3):364-372. doi: ... IMPT was the only factor associated with significantly lower likelihood of developing grade 3 or greater acute … troubleshoot klipsch promedia 2.1Witryna12 kwi 2024 · Lymph node status is an important long-term prognostic factor for patients with iCCA. 32 Specifically, the presence of lymph node metastases not only adversely affects OS but also influences the relative effect of tumor number and vascular invasion on survival. 33 Therefore, assessment of the nodal basin should be performed at … troubleshoot kms serverWitrynaThis study aims to show that split-course therapy may achieve good local control tumor response rates at 6 months for those patients who are unfit to tolerate continuous therapy, and may be better tolerated, with decreased side effects. 103 Appropriate patient selection is critical, given that split-course therapy carries the potential risk of ... troubleshoot kitchenaid stand mixerWitrynaUnadjusted and Adjusted effect for the tumor for DFS, OS and SAR in the molecular subgroups population ... with or without cetuximab: a post hoc analysis of the PETACC-8 trial. [Published online January 14, 2016]. JAMA Oncol. doi:10.1001/jamaoncol ... Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in … troubleshoot kodak easyshare cameratroubleshoot konica